ReviewNature reviews. Rheumatology2024
Epstein-Barr virus as a potentiator of autoimmune diseases.
Review in Nature reviews. Rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed.
- Review
- Epstein-Barr Virus: More than Just an Infection.Viruses · 2026Review
- Epstein-Barr Virus-Induced Acute Pancreatitis-A Case Report and a Review of Literature.Reports (MDPI) · 2026Article
- DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy.MedComm · 2026Review
- Activation of Anergic B Cells During Development of Autoimmunity.Immunological reviews · 2026Review
- Possible involvement of viral infection in the pathogenesis of myasthenia gravis.Journal of neurovirology · 2026Review
- Article
- "IL-40: A novel immunoregulatory axis at the crossroads of inflammation, tissue remodeling, and cancer immunity".Immunologic research · 2026Review
- A tonsil organoid model reveals Epstein-Barr virus-infected germinal center B cell states during primary infection.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Systematic investigation reveals extensive Epstein-Barr virus transcriptional regulation of the human genome.Cell genomics · 2026Article
- Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts.Blood cancer journal · 2026Article
- Unconventional functions of natural killer cells in homeostasis and disease.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- The EBNA-1 Conundrum: Does Epstein-Barr Virus Invoke Autoimmune Pathology in a Population Subset by Poorly Purine-Loading Its Major Latency-Maintaining Transcript?Scandinavian journal of immunology · 2026Review
- Decoding the association between microorganisms and autoimmunity: a multifaceted review of evidence on specific pathogens that trigger autoimmune diseases.Clinical and experimental medicine · 2026Review
- The clinical features, pathological assessment, and prognostic analysis of autoimmune hepatitis in Chinese persons living with HIV.BMC infectious diseases · 2026Article
- Identification of a shared antigen linking CD4Science advances · 2026Article
- Biomarkers associated with Hashimoto's thyroiditis induced by viral infection: An integrative bioinformatics and machine learning.Journal of translational autoimmunity · 2026Article
- Epidemiological Trends and Clinical Characteristics of Epstein-Barr Virus Infection in Febrile Children in Zhejiang, China: A Retrospective Study.Immunity, inflammation and disease · 2026Article
- Analysis Of Salivary Herpesviruses Reveals Associations Between HHV-6 And Long COVID Severity.medRxiv : the preprint server for health sciences · 2026Article
- Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Epstein-Barr virus (EBV) is epidemiologically associated with development of autoimmune diseases, including systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis and multiple sclerosis. Although there is well-established evidence for this association, the underlying mechanistic basis remains incompletely defined. In this Review, we discuss the role of EBV infection as a potentiator of autoimmune rheumatic diseases. We review the EBV life cycle, viral transcription programmes, serological profiles and lytic reactivation. We discuss the epidemiological and mechanistic associations of EBV with systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis and multiple sclerosis. We describe the potential mechanisms by which EBV might promote autoimmunity, including EBV nuclear antigen 1-mediated molecular mimicry of human autoantigens; EBV-mediated B cell reprogramming, including EBV nuclear antigen 2-mediated dysregulation of autoimmune susceptibility genes; EBV and host genetic factors, including the potential for autoimmunity-promoting strains of EBV; EBV immune evasion and insufficient host responses to control infection; lytic reactivation; and other mechanisms. Finally, we discuss the therapeutic implications and potential therapeutic approaches to targeting EBV for the treatment of autoimmune disease.
Indexed as
Identifiers
39390260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.